Anaptysbio (ANAB) Long-Term Investments (2017 - 2025)
Anaptysbio's (ANAB) quarterly Long-Term Investments came in at $7.7 million in Q3 2025, down 72.42% YoY from $27.9 million in Q3 2024, and down 72.5% on a QoQ basis from $28.0 million in Q2 2025.
Anaptysbio (ANAB) Long-Term Investments (2017 - 2025) Analysis & Trends
Anaptysbio (ANAB) has 9 years of Long-Term Investments data on file, last reported at $7.7 million in Q3 2025.
- Quarterly Long-Term Investments fell 72.42% year-over-year to $7.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.7 million (down 72.42% YoY) and the FY2024 annual result came in at $35.5 million, up 31.24% from the prior year.
- Long-Term Investments slipped to $7.7 million in Q3 2025, from $28.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $147.5 million in Q3 2022 to a low of $5.5 million in Q2 2021.
- A 5-year average of $54.1 million and a median of $40.2 million in 2023 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2021 — Long-Term Investments slumped 85.95% — and 2022, when it surged 2270.26%.
- Tracing ANAB's Long-Term Investments over 5 years: stood at $67.1 million in 2021, then jumped by 113.03% to $142.9 million in 2022, then sank by 81.09% to $27.0 million in 2023, then jumped by 31.24% to $35.5 million in 2024, then plunged by 78.3% to $7.7 million in 2025.
- The last three Long-Term Investments figures came in at $7.7 million (Q3 2025), $28.0 million (Q2 2025), and $43.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.70 Mn |
| Jun 30, 2025 | 28.00 Mn |
| Mar 31, 2025 | 43.02 Mn |
| Dec 31, 2024 | 35.47 Mn |
| Sep 30, 2024 | 27.91 Mn |
| Jun 30, 2024 | 42.65 Mn |
| Mar 31, 2024 | 15.47 Mn |
| Dec 31, 2023 | 27.03 Mn |
| Sep 30, 2023 | 40.20 Mn |
| Jun 30, 2023 | 59.24 Mn |
| Mar 31, 2023 | 94.93 Mn |
| Dec 31, 2022 | 142.94 Mn |
| Sep 30, 2022 | 147.51 Mn |
| Jun 30, 2022 | 129.99 Mn |
| Mar 31, 2022 | 91.20 Mn |
| Dec 31, 2021 | 67.10 Mn |
| Sep 30, 2021 | 15.24 Mn |
| Jun 30, 2021 | 5.48 Mn |
| Mar 31, 2021 | 7.06 Mn |
| Dec 31, 2020 | 17.55 Mn |